Preclinical mouse models and pilot human studies involving CD40 agonist antibodies in combination with gemcitabine in the treatment of pancreatic cancer have shown that CD40 activation helps reverse immunosuppression with modest tumor response rates [246]. Here, CD40 is linked to pancreatic neoplasm.